Abstract 4705
Background
Falls are one of the best safety indicators in hospitalized cancer patients. In 2013, a security group was created to promote a culture for patient safety, to prevent, register and analyses falls at 3 cancer centers of Catalan Institute of Oncology. WHO defined falls as the result of an incident that precipitates the patients down involuntarily, includes slipping, tripping and loss of body balance. A systematic review by Wildes (2015), risk factors for hospitalized cancer patients are different from the general patient. Objective: Identify predisposing factors to fall and define the profile of the hospitalized cancer patient with higher risk to fall.
Methods
A cross-sectional, multisite study. Inclusion: patients hospitalized in 3 centers during 2017. Data recruited as voluntary report of falls in a computerized system. Variables: socio-demographic, clinical and environmental factors.
Results
118 falls were reported; 48(40.68%) in Hospitalet; 36(30.51%) in Badalona and 34(28.81%) in Girona. Falls rate was 2.53‰, with lesion was 0.41‰ and severe lesion was 1.35% in one center. Nurses initially classified patients according to Stratify®: high risk 68(59.13%) and 47(40.87%) low-risk. A previous history of fall in last 6 months was for 18(15.25%). By diagnosis 39(33.06%) was lung and head-neck, hematologic 27(22.88%) and colorectal & GI 22(18.68%). The main cause of fall were loss of balance 31(26.50%), lack of strength/ weakness 26(22.22%) and slide 20(17.09%). Location at the hospital was 65 (55.08%) in oncology services, 29(24.58%) in hematology unit and 24(20.34%) in palliative care. Contributing factors was a risky medication 113(96.58%). Factors as being alone 69(58.47%), impairment of mobility 86(73.5%) and patient does not perceived any risk 101(89.38%).
Conclusions
Lung or head-neck neoplasia, medication of risk, mobility problems and the low perception of risk were the common factors resulting associated with a fall. Pautex 2008 indicated a similar rate than our for cancer patients. Room to improve for identification of the patient according to their risk is not enough but, some activities after assessment are needed. Stratify® does not fit properly to define factors related to cancer like anemia, fatigue, chemotherapy or pain.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5056 - Phase 2 study of 2 dosing regimens of cemiplimab, a human monoclonal anti–PD-1, in metastatic cutaneous squamous cell carcinoma (mCSCC)
Presenter: Danny Rischin
Session: Poster Display session 3
Resources:
Abstract
5710 - Avelumab for advanced Merkel cell carcinoma in the Netherlands; a nationwide survey
Presenter: Sonja Levy
Session: Poster Display session 3
Resources:
Abstract
3152 - Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data
Presenter: Sandra D'Angelo
Session: Poster Display session 3
Resources:
Abstract
5715 - A Phase 2, Randomized Study of Nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and Stereotactic Body Radiation Therapy (SBRT) for Metastatic Merkel Cell Carcinoma (MCC, NCT03071406) – a preliminary report.
Presenter: Sungjune Kim
Session: Poster Display session 3
Resources:
Abstract
2854 - Real-world impact of immune checkpoint inhibitors in metastatic uveal melanoma
Presenter: Kalijn Bol
Session: Poster Display session 3
Resources:
Abstract
2928 - Immune checkpoint inhibitors in a cohort of 206 metastatic uveal melanomas patients
Presenter: Mathilde Saint-Ghislain
Session: Poster Display session 3
Resources:
Abstract
1235 - Incidence and survival of Uveal Melanoma occurring as single cancer versus its occurrence as a first or second primary neoplasm
Presenter: Ahmad Alfaar
Session: Poster Display session 3
Resources:
Abstract
3615 - Validation of a Clinicopathological and Gene Expression Profile (CP-GEP) Model for Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma
Presenter: Evalyn Mulder
Session: Poster Display session 3
Resources:
Abstract
1793 - External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC) using the Surveillance, Epidemiology and End Results (SEER) Program
Presenter: Angelina Tjokrowidjaja
Session: Poster Display session 3
Resources:
Abstract
4278 - Clinical factors and overall survival (OS) associated with patterns of metastases (mets) in melanoma patients (pts).
Presenter: Ines Pires da Silva
Session: Poster Display session 3
Resources:
Abstract